Trial Profile

Real World Utilization of Upadacitinib in Adult and Adolescent Patients Living With Moderate to Severe Atopic Dermatitis (AD-VISE)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Upadacitinib (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Acronyms AD-VISE
Sponsors AbbVie

Most Recent Events

27 Mar 2026 According to a Abbvie media release, data from this trial will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27 to 31 in Denver, Colorado.
14 Aug 2025 Planned End Date changed from 15 Oct 2026 to 1 Oct 2026.
14 Aug 2025 Planned primary completion date changed from 31 Oct 2025 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com